Press Release Sep 12 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its final approval from the USFDA for Cariprazine Capsules, which includes shared exclusivity for a period. The approval allows Zydus to market multiple strengths of Cariprazine Capsules, an atypical antipsychotic used for treating schizophrenia and bipolar disorder. The drug will be manufactured at Zydus's facility in Ahmedabad, India, and had significant annual sales in the United States according to market data.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 09 2022
- Press Release Sep 07 2022
- Press Release Aug 31 2022
- Press Release Aug 30 2022
- Press Release Aug 11 2022
Later from Zydus Lifesciences
- Press Release Sep 13 2022
- Press Release Sep 16 2022
- Press Release Sep 20 2022
- Press Release Oct 01 2022
- Press Release Oct 03 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences